Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 3/20 | 0.66 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.66 |
| ▸ | CA12 | O43570 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | CA4 | P22748 | 4/20 | 0.64 |
| ▸ | CA9 | Q16790 | 4/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340500 | 1.00 | CXCR1 (0.66) | CXCR1CXCR2CA12CA1CA2 | |
| SCHEMBL15369139 | 0.89 | CA12 (0.64) | CXCR1CXCR2CA12CA1CA2 | |
| SCHEMBL12608940 | 0.89 | CA12 (0.64) | CXCR1CXCR2CA12CA1CA2 | |
| SCHEMBL15343987 | 0.89 | CA12 (0.64) | CXCR1CXCR2CA12CA1CA2 | |
| SCHEMBL918413 | 0.84 | CA12 (0.62) | CXCR1CXCR2CA12CA1CA2 | |
| Mabuprofen SCHEMBL51633 | 0.82 | CHRM1 (0.67) | CXCR1CXCR2CA12CA1CA2 | |
| SCHEMBL6675668 | 0.81 | CHRM1 (0.65) | CXCR1CXCR2CA12CA1CA2 | |
| SCHEMBL6069869 | 0.81 | CHRM1 (0.65) | CXCR1CXCR2CA12CA1CA2 | |
| SCHEMBL12613755 | 0.81 | CHRM1 (0.65) | CXCR1CXCR2CA12CA1CA2 | |
| SCHEMBL24045921 | 0.80 | TRPV1 (0.64) | CXCR1CXCR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | CXCR1 4600/4885CXCR2 3532/4885CA12 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.